Clinical trials: Clinical Research
Acromegaly
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
Octreotide capsule is a novel, orally-administered formulation of the commercially-available injectable drug octreotide. In a recent phase 3 trial, oral octreotide capsules demonstrated maintenance of biochemical response up to…
- Trial name
- OPTIMAL (NCT03252353)
- Testing
- octreotide capsules
- Where
- 60 sites in United States, Australia and 15 more
- Volunteers
- 56 people
- Sponsor
- Chiasma, Inc.
Carcinoma, Non-Small-Cell Lung, Melanoma
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
This is a phase I/Ib, open label study. The escalation portion will characterize the safety and tolerability of DKY709 and DKY709 in combination with PDR001 in subjects with NSCLC or melanoma who have received prior…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Melanoma, Nasopharyngeal Carcinoma, Microsatellite Stable Colorectal Cancer
- Trial name
- NCT03891953
- Testing
- DKY709, PDR001
- Where
- 9 sites in United States, Germany and 4 more
- Volunteers
- 98 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
A Study of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and A Second Controller Medication (VERSE)
This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will assess the efficacy and safety of lebrikizumab in patients with asthma whose disease remains uncontrolled despite daily therapy with an…
- Trial name
- NCT01545453
- Testing
- lebrikizumab
- Where
- 63 sites in United States, Australia
- Volunteers
- 205 people
- Sponsor
- Genentech, Inc.
Influenza
A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2009/2010 Influenza Virus Strains for the Northern Hemisphere
This study is to assess whether the Northern Hemisphere 2009/2010 season influenza vaccine Inflexal V fulfills the EMEA requirements for re-registration of influenza vaccines.
- Trial name
- NCT01306253
- Testing
- Inflexal V
- Where
- Switzerland
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
West Nile Fever
An Exploratory Study of AVI-4020 in Patients With Possible Acute Neuroinvasive West Nile Virus (WNV) Disease
Although the serious form of West Nile Virus (WNV) disease, referred to as neuroinvasive disease, is rare, it can result in permanent disabilities and occasionally death.
- Trial name
- NCT00091845
- Testing
- AVI-4020 Injection
- Volunteers
- 50 people
- Sponsor
- Sarepta Therapeutics, Inc.
Healthy Volunteers
Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20
This is a single center, Phase I, open-label, single-blind (subjects blinded to the contents of each injection), 4 stage study designed to determine the PK, GD, safety, tolerability, and optimal ratio of rHuPH20 administered with…
- Trial name
- NCT00803972
- Testing
- rHuPH20, Insulin Human Injection, Insulin Lispro Injection
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Halozyme Therapeutics
Venous Thromboembolism
Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis
The purpose of this study is to determine the optimal dose of BAY 59-7939 and to compare the safety and effectiveness of this new drug with the standard way of treatment of deep vein thrombosis (heparin infusion plus one of the…
- Trial name
- NCT00395772
- Testing
- Xarelto (Rivaroxaban, BAY59-7939), (LMW) Heparin + Vitamin K Antagonist
- Where
- 78 sites in United States, Australia and 11 more
- Volunteers
- 543 people
- Sponsor
- Bayer
Relapsed or Refractory Lymphoid Malignancies
A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies
This is an open-label Phase 1a dose escalation study of single-agent OMP-52M51 in subjects with relapsed or refractory lymphoid malignancies. Study includes a dose escalation phase and expansion phase.
- Trial name
- NCT01703572
- Testing
- OMP-52M51
- Where
- 10 sites in United States
- Volunteers
- 24 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Myelodysplastic Syndrome
The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)
Evaluation of the Efficacy and Safety of Oral Azacitidine plus Best Supportive care versus Placebo and Best Supportive care in subjects with red blood cell (RBC) transfusion-dependent anemia and thrombocytopenia due to…
- Trial name
- NCT01566695
- Testing
- Oral Azacitidine, Best Supportiv Care (BSC)
- Where
- 196 sites in United States, Australia and 21 more
- Volunteers
- 216 people
- Sponsor
- Celgene
Healthy, Type 1 Diabetes
Subcutaneous Administration of Lisofylline to Healthy Normal Subjects and Subjects With Type 1 Diabetes
Type 1 diabetes mellitus (T1DM) is an autoimmune disease. Autoimmune diseases happen when the immune system does not identify part of the body as belonging to it.
- Trial name
- NCT00896077
- Testing
- Lisofylline
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- DiaKine Therapeutics, Inc.
Photo-damage
Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, 0.015%, in Patients With Photo-damaged Skin
This study is primarily designed to evaluate the safety and tolerability of PEP005 Gel, 0.015% when administered for up to three consecutive days to photo-damaged skin on the face.
- Trial name
- NCT01214577
- Testing
- PEP005 (ingenol mebutate) Gel
- Where
- 2 sites in Australia
- Volunteers
- 24 people
- Sponsor
- Peplin
Type2 Diabetes Mellitus, Chronic Kidney Disease
A Study of ONO-3310 in Healthy Adult Male Subjects and Chronic Kidney Disease Patients With Type 2 Diabetes Mellitus
To investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of ONO-3310 in healthy Japanese adult male subjects and chronic kidney disease patients with type 2 diabetes…
- Trial name
- NCT07619157
- Testing
- ONO-3310
- Where
- Japan
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Influenza, Human
Pharmacokinetics of Zanamivir After Single and Repeated Dose Infusion Administration in Healthy Chinese Adults
Zanamivir is a potent and highly selective inhibitor of the influenza virus neuraminidase. Intravenous (IV) zanamivir is being developed for treatment of hospitalized patients with influenza, especially for those patients who may…
- Trial name
- NCT02377401
- Testing
- Zanamivir
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Select Advanced Solid Tumors
First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors
CDR404 is a highly potent and specific T-cell engaging bispecific and bivalent antibody designed for the treatment of cancers positive for the tumor-associated antigen melanoma-associated antigen 4 (MAGE-A4).
- Trial name
- NCT06402201
- Testing
- CDR404
- Where
- 20 sites in United States, Belgium and 4 more
- Volunteers
- 42 people
- Sponsor
- CDR-Life AG
Prostate Cancer
Study of TRDC002 in the Diagnosis of Patients With PSMA-positive Prostate Cancer
TRDC002 uses a radioactive form (64Cu) to trace the PSMA positive prostate cancer. The purpose of this study is to investigate TRDC002 as a PSMA PET tracer to localize PSMA positive lesions in adult patients with recurrent or…
- Trial name
- NCT07236112
- Testing
- Intravenous (IV) single dose
- Where
- 2 sites in China
- Volunteers
- 6 people
- Sponsor
- C Ray Therapeutics
Cystic Fibrosis
Study of GLPG1837 in Subjects With Cystic Fibrosis (S1251N Mutation)
At least 6 cystic fibrosis patients with the S1251N mutation will be treated for 4 weeks, consisting of two consecutive treatment periods of two weeks evaluating one dose of GLPG1837 each.
- Trial name
- SAPHIRA2 (NCT02690519)
- Testing
- GLPG1837 dose 1, GLPG1837 dose 2
- Where
- 5 sites in Belgium, Netherlands
- Volunteers
- 7 people
- Sponsor
- Lakefront Biotherapeutics NV
Hepatitis B
Safety and Antiviral Activity of Clevudine in Patients Infected With Hepatitis B Virus
The purpose of this study is to determine the antiviral effects and safety of clevudine 30 mg once a day (QD) and 50 mg QD in patients infected with hepatitis B virus (HBV).
- Trial name
- NCT00305019
- Testing
- clevudine
- Where
- 8 sites in South Korea
- Volunteers
- 120 people
- Sponsor
- Bukwang Pharmaceutical
Pancreatic Carcinoma
Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer
The purpose of this study is to demonstrate that preoperative biliary drainage using self-expanding metal stents (SEMS) does not negatively impact overall surgical outcomes in patients undergoing pancreaticoduodenectomy for…
- Trial name
- NCT01774019
- Testing
- WallFlex™ Biliary RX Fully Covered/Uncovered Stent System
- Where
- 11 sites in United States, Australia and 7 more
- Volunteers
- 284 people
- Sponsor
- Boston Scientific Corporation
Bronchiectasis Adult
Study on Doses of Inhaled ALX1 in Adults With Bronchiectasis
This study will evaluate the safety and effects of ALX1, an inhaled investigational treatment, in adults with bronchiectasis. Participants will receive either ALX1 or a placebo (a treatment with no active medicine) for 14 days.
- Trial name
- NCT07731919
- Testing
- ALX1
- Volunteers
- 28 people
- Sponsor
- Vast Therapeutics
Meningoccocal Disease, Meningococcal Meningitis
Antibody Persistence, and Safety and Tolerability of a Booster Dose of the Meningococcal B Vaccine After the Completion of the Vaccination Course in Study V72_28
The aim of this extension study is to explore the antibody persistence 24 to 36 months after the last dose of vaccine, in infants that received a two or three dose primary series plus a booster dose at 11 months of age, of the…
- Trial name
- NCT01894919
- Testing
- Bexsero® vaccine (1 dose at study month zero), Bexsero® vaccine (2 doses 1 month apart)
- Where
- 17 sites in Hungary, Spain
- Volunteers
- 851 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.